Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
| Website: | galmedpharma.com |
| Email: | info@galmedpharma.com |
| Main Phone: | +972 36938448 |
| Address: | 16 Tiomkin Street |
| City / Town: | Tel Aviv |
| Country: | ISR |
| Postal Code: | 6578317 |
| Exchange: | NSC |
| CEO: | Allen Baharaff |
| Employees: | 21 |
| NAICS: | Pharmaceutical P |
Gathering Data... Please wait Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
| Website: | galmedpharma.com |
| Email: | info@galmedpharma.com |
| Main Phone: | +972 36938448 |
| Address: | 16 Tiomkin Street |
| City / Town: | Tel Aviv |
| Country: | ISR |
| Postal Code: | 6578317 |
| Exchange: | NSC |
| CEO: | Allen Baharaff |
| Employees: | 21 |
| NAICS: | Pharmaceutical P |
| Last Price 6.61 | Change $ -0.21 | Change % -3.08 | Tick N/A |
| Bid 4.50 | Bid Size 2,000.00 | Ask 8.14 | Ask Size 1,000.00 |
| Open 6.68 | High 6.96 | Low 6.61 | Prev Close 6.82 |
| Last Trade | Volume 22,814 | 52 Wk Hi 15.98 | 52 Wk Low 5.48 |
| Market Cap 139.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 21,113,066.00 | EPS (TTM) -0.57 | PE Ratio N/A | Exchange NCM |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 32 | 32 | 32 | 43 |
| Low Target Price Estimate | 14 | 14 | 14 | 30 |
| Mean Target Price Estimate | 20.8 | 20.8 | 20.8 | 33.2 |
| Standard Deviation | 7.4 | 7.4 | 7.4 | 5.54 |
| Date of Most Recent Estimate | 05/23/18 | 05/23/18 | 05/23/18 | 06/14/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| FWP | Free Writing Prospectus | 27 | 2018-06-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 33 | 2018-06-18 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 72 | 2018-06-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 8 | 2018-06-12 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 20 | 2018-05-09 |
| SC 13G | Statement of beneficial ownership of common stock by certain persons | 14 | 2018-04-16 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 48 | 2018-04-04 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 54 | 2018-04-04 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-04-03 |
| UPLOAD | Correspondence from the SEC to the Filer | 1 | 2018-04-02 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1.4 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
